516 related articles for article (PubMed ID: 30337220)
1. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
Velikova G; Williams LJ; Willis S; Dixon JM; Loncaster J; Hatton M; Clarke J; Kunkler IH; Russell NS;
Lancet Oncol; 2018 Nov; 19(11):1516-1529. PubMed ID: 30337220
[TBL] [Abstract][Full Text] [Related]
2. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova G; Morden JP; Haviland JS; Emery C; Barrett-Lee P; Earl H; Bloomfield D; Brunt AM; Canney P; Coleman R; Verrill M; Wardley A; Bertelli G; Ellis P; Stein R; Bliss JM; Cameron D;
Lancet Oncol; 2023 Dec; 24(12):1359-1374. PubMed ID: 37926100
[TBL] [Abstract][Full Text] [Related]
3. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
Schäfer R; Strnad V; Polgár C; Uter W; Hildebrandt G; Ott OJ; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Gall C; Polat B;
Lancet Oncol; 2018 Jun; 19(6):834-844. PubMed ID: 29695348
[TBL] [Abstract][Full Text] [Related]
4. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
7. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Kunkler IH; Williams LJ; Jack WJ; Cameron DA; Dixon JM;
Lancet Oncol; 2015 Mar; 16(3):266-73. PubMed ID: 25637340
[TBL] [Abstract][Full Text] [Related]
8. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
9. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
Poortmans PM; Weltens C; Fortpied C; Kirkove C; Peignaux-Casasnovas K; Budach V; van der Leij F; Vonk E; Weidner N; Rivera S; van Tienhoven G; Fourquet A; Noel G; Valli M; Guckenberger M; Koiter E; Racadot S; Abdah-Bortnyak R; Van Limbergen EF; Engelen A; De Brouwer P; Struikmans H; Bartelink H;
Lancet Oncol; 2020 Dec; 21(12):1602-1610. PubMed ID: 33152277
[TBL] [Abstract][Full Text] [Related]
10. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Kitchener HC; Nijman HW; Kruitwagen RF; Nout RA; Verhoeven-Adema KW; Smit VT; Putter H; Creutzberg CL;
Lancet Oncol; 2016 Aug; 17(8):1114-1126. PubMed ID: 27397040
[TBL] [Abstract][Full Text] [Related]
12. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.
Hopwood P; Haviland JS; Sumo G; Mills J; Bliss JM; Yarnold JR;
Lancet Oncol; 2010 Mar; 11(3):231-40. PubMed ID: 20138809
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial.
Veronesi U; Orecchia R; Maisonneuve P; Viale G; Rotmensz N; Sangalli C; Luini A; Veronesi P; Galimberti V; Zurrida S; Leonardi MC; Lazzari R; Cattani F; Gentilini O; Intra M; Caldarella P; Ballardini B
Lancet Oncol; 2013 Dec; 14(13):1269-77. PubMed ID: 24225155
[TBL] [Abstract][Full Text] [Related]
15. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: Health-related quality of life final analysis from the Florence phase 3 trial.
Meattini I; Saieva C; Miccinesi G; Desideri I; Francolini G; Scotti V; Marrazzo L; Pallotta S; Meacci F; Muntoni C; Bendinelli B; Sanchez LJ; Bernini M; Orzalesi L; Nori J; Bianchi S; Livi L
Eur J Cancer; 2017 May; 76():17-26. PubMed ID: 28262584
[TBL] [Abstract][Full Text] [Related]
16. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles CE; Griffin CL; Kirby AM; Titley J; Agrawal RK; Alhasso A; Bhattacharya IS; Brunt AM; Ciurlionis L; Chan C; Donovan EM; Emson MA; Harnett AN; Haviland JS; Hopwood P; Jefford ML; Kaggwa R; Sawyer EJ; Syndikus I; Tsang YM; Wheatley DA; Wilcox M; Yarnold JR; Bliss JM;
Lancet; 2017 Sep; 390(10099):1048-1060. PubMed ID: 28779963
[TBL] [Abstract][Full Text] [Related]
17. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A; Haviland JS; Wheatley DA; Sydenham MA; Alhasso A; Bloomfield DJ; Chan C; Churn M; Cleator S; Coles CE; Goodman A; Harnett A; Hopwood P; Kirby AM; Kirwan CC; Morris C; Nabi Z; Sawyer E; Somaiah N; Stones L; Syndikus I; Bliss JM; Yarnold JR;
Lancet; 2020 May; 395(10237):1613-1626. PubMed ID: 32580883
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
20. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
; Bentzen SM; Agrawal RK; Aird EG; Barrett JM; Barrett-Lee PJ; Bliss JM; Brown J; Dewar JA; Dobbs HJ; Haviland JS; Hoskin PJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Morgan DA; Owen JR; Simmons S; Sumo G; Sydenham MA; Venables K; Yarnold JR
Lancet Oncol; 2008 Apr; 9(4):331-41. PubMed ID: 18356109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
